ProfileGDS5678 / 1421119_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 66% 66% 65% 66% 67% 66% 66% 65% 66% 66% 62% 66% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0183866
GSM967853U87-EV human glioblastoma xenograft - Control 23.945966
GSM967854U87-EV human glioblastoma xenograft - Control 33.9693866
GSM967855U87-EV human glioblastoma xenograft - Control 43.8815465
GSM967856U87-EV human glioblastoma xenograft - Control 53.9330366
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1080567
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.04566
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9501366
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9479665
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9644566
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9432766
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6994962
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9559366
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9610966